PROUS SCIENCE INTEGRITY. Leukemia Therapy: Bcr-Abl Kinase Inhibitors: Selective vs Nonselective

Similar documents
Tasigna. Tasigna (nilotinib) Description

Tasigna. Tasigna (nilotinib) Description

Allergy Basics. This handout describes the process for adding and removing allergies from a patient s chart.

Bosulif. Bosulif (bosutinib) Description

Blood Cancer: Chronic Myelogenous Leukaemia

Module 3: Pathway and Drug Development

CHRONIC MYELOGENOUS LEUKEMIA. By Ting Huai Shi Pd. 6

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY)

A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL

BLOOD AND LYMPH CANCERS

Patient information brochure

CIBMTR Center Number: CIBMTR Recipient ID: Today s Date: Date of HSCT for which this form is being completed:

Add_A_Class_with_Class_Search_Revised Thursday, March 18, 2010

Peking University People's Hospital, Peking University Institute of Hematology

Self Assessment 8.3 to 8.4.x

Add_A_Class_with_Class_Number_Revised Thursday, March 18, 2010

PBSI-EHR Off the Charts!

Clinical Policy: Nilotinib (Tasigna) Reference Number: CP.CPA.162 Effective Date: Last Review Date: Line of Business: Commercial

Personalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center

Exercise Pro Getting Started Guide

Refilling a Prescription with No Refills Remaining

HEMATOPOIETIC CELL TRANSPLANTATION FOR CHRONIC MYELOID LEUKEMIA

Recommended Timing for Transplant Consultation

Titrations in Cytobank

See Important Reminder at the end of this policy for important regulatory and legal information.

Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. (NILOdeepR)

How a CML Patient and Doctor Work Together

What is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias

a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation

Chronic Myelogenous Leukemia (Hematology) By DEISSEROTH READ ONLINE

Chapter 1: Managing workbooks

BCCA Protocol Summary for Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using PONAtinib

Gleevec. Gleevec (imatinib) Description

Leukemias. Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College

CHAPTER:4 LEUKEMIA. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY 8/12/2009

Hematologic Malignancies 2013 Retrospective Study at Truman Medical Center

Synribo (Chronic Myeloid Leukemia)

PedCath IMPACT User s Guide

Philadelphia Positive (Ph+) Chronic Myeloid Leukaemia

The Future of Chronic Myelogenous Leukemia: New Treatments on the Horizon

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017

Distribution of Leukemia in Chennai Population:- An Epidemiological Study

Leukemias and Lymphomas Come From Normal Blood Cells

screening procedures Disease resistant to full-dose imatinib ( 600 mg/day) or intolerant to any dose of imatinib

Cancer and Tyrosine Kinase Inhibition

Myeloproliferative Disorders - D Savage - 9 Jan 2002

Facts On Leukemia By American Cancer Society

NIH BIOSKETCH CLINIC

Facts LEUKEMIA LYMPHOMA MYELOMA

Leukemia. There are different types of leukemia and several treatment options for each type.

Chronic Myeloid Leukemia (CML)

July 3, The Physician Compare Team Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244

A medicine to block the amount of acid produced in the stomach (H2 blocker): about 10 hours before about 2 hours after

JAK2 V617F analysis. Indication: monitoring of therapy

Age Disparity in the Dissemination of Imatinib Mesylate (Gleevec) for Treating Chronic Myeloid Leukemia

TRANSPARENCY COMMITTEE OPINION. 14 February 2007

See Important Reminder at the end of this policy for important regulatory and legal information.

Part 2: Cancer Therapies, Present and Future. Adrianna San Roman Leah Liu Clare Malone

Chronic Pain Management Workflow Getting Started: Wrenching In Assessments into Favorites (do once!)

Previous Study Return to List Next Study

ProScript User Guide. Pharmacy Access Medicines Manager

TARGETED THERAPY FOR CHILDHOOD CANCERS

Instructor Guide to EHR Go

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia

BE THE MATCH. The Role of HLA in Finding a Match for Bone Marrow or Peripheral Blood Stem Cell Transplantation

See Important Reminder at the end of this policy for important regulatory and legal information.

Ponatinib Withdrawal Update

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

CML David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML Current treatment options for CML

Donor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant

Form 2011 R4.0: Acute Lymphoblastic Leukemia (ALL) Pre-HCT Data

MAGIC BULLETS A CASE ON ENZYME INHIBITION

Precision Medicine Knowledgebase (PMKB)

An Initiative to Equip Health-System Pharmacists to Select and Manage Drug Therapy for the Disease

See Important Reminder at the end of this policy for important regulatory and legal information.

THE USE OF WT1-QPCR TO MEASURE AND DETECT MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA. Ava Greco

hmhco.com National GO Math! K 6 USER GUIDE Personal Math Trainer Powered by Knewton

Charge Posting. General Principles. Insurance Payments for Services

Here are the various choices. All of them are found in the Analyze menu in SPSS, under the sub-menu for Descriptive Statistics :

Jeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ

See Important Reminder at the end of this policy for important regulatory and legal information.

Creating YouTube Captioning

Setting The setting was secondary care. The economic study was carried out in the UK.

Leukemia (The Biology of Cancer)

MPL W515L K mutation

Index. Note: Page numbers of article titles are in boldface type.

Special pediatric considerations are noted when applicable, otherwise adult provisions apply.

Targeted Medicine and Molecular Therapeutics. Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009

The Clinical Information Data Entry Screen is the main screen in the DQCMS application.

Technology appraisal guidance Published: 21 December 2016 nice.org.uk/guidance/ta426

Dementia Direct Enhanced Service

Technology appraisal guidance Published: 21 December 2016 nice.org.uk/guidance/ta425

DOWNLOAD OR READ : TREATMENT OF ACUTE LEUKEMIAS NEW DIRECTIONS FOR CLINICAL RESEARCH REPRINT PDF EBOOK EPUB MOBI

Vocabulary: cell division, centriole, centromere, chromatid, chromatin, chromosome, cytokinesis, DNA, interphase, mitosis

Making a Room Reservation with Service Requests in Virtual EMS

Moffitt s Program In Malignant Hematology: A decade of discovery: from cytotoxic treatments to targeted therapies

Transcription:

PROUS SCIENCE INTEGRITY Leukemia Therapy: Bcr-Abl Kinase Inhibitors: Selective vs Nonselective

SUMMARY In this use case, active compounds for Leukemia will be found and filtered by mechanisms of action and organization. Comparing two launched products for this condition, Gleevec and Tasigna, a structure search will be run to find structure-activity relationships for specific Bcr-Abl kinase inhibitors. From specific Abl kinase inhibitors list, related targets associated to these drugs will be examined and the targetscape for Acute Myeloiod Leukemia will be explored

LEUKEMIA Leukemia is a malignant disease of the bone marrow and blood that is characterized by the uncontrolled accumulation of white blood cells About 4,400 people in the U.S. will die of Chronic lymphocytic leukemia during 2009, according to the American Cancer Society. Among patients with Acute lymphocytic leukemia in the U.S., approximately 1,400 are predicted to die during the same year; two-thirds of these would be adults. Approximately 470 people with Chronic myelogenous leukemia and 9,000 with Acute myelogenous leukemia are expected to die as a cause of their disease this year in the U.S. The treatment of leukemia is complex and is based on a range of factors including characteristics of the disease itself (type of leukemia, extent of disease, whether or not the disease has been treated previously) and patient characteristics (age, symptoms and general health). Chemotherapy is the primary treatment for acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL), although the specific drugs used to treat each form differ. In some cases radiotherapy or stem cell transplantation may be used in combination with chemotherapy.

DRUGS & BIOLOGICS KNOWLEDGE AREA: GUIDED SEARCH Go to the Drugs & Biologics Knowledge Area from the pull down menu at the left part of the home page of Integrity

DRUGS & BIOLOGICS KNOWLEDGE AREA: GUIDED SEARCH Click the down arrow to open the pull-down of search fields and select Development Status -> Condition in this example.

DRUGS & BIOLOGICS KNOWLEDGE AREA: GUIDED SEARCH Next open the Browse Index of search terms for the search field chosen, run a preliminary lookup search to locate a term in the index, and then click the term on the right to copy it to the Search Form.

DRUGS & BIOLOGICS KNOWLEDGE AREA: GUIDED SEARCH Add other relevant criteria to the Search Form in this example, select Development Status -> Under Active Development = Y Click Start or hit return to launch the search.

DRUGS & BIOLOGICS KNOWLEDGE AREA: GUIDED SEARCH From the list of active development programs for leukemia, retrieve the corresponding products by selecting the Product List from the Options pulldown menu

DRUGS & BIOLOGICS KNOWLEDGE AREA: GUIDED SEARCH Use the Filter by Statistics charts to further limit the search. From the Product List obtained, filter by Organization

DRUGS & BIOLOGICS KNOWLEDGE AREA: GUIDED SEARCH Check the companies of interest and click View Subset(s) In this example, select the Novartis and Novartis Oncology checkboxes

DRUGS & BIOLOGICS KNOWLEDGE AREA: GUIDED SEARCH Select the Full Record option from the Options pull-down menu

DRUGS & BIOLOGICS KNOWLEDGE AREA: GUIDED SEARCH The product record for Imatinib mesylate shows that it acts on multiple targets, including Abl Kinase and Bcr- Abl Kinase

DRUGS & BIOLOGICS KNOWLEDGE AREA: GUIDED SEARCH The product record for Nilotinib Hydrochloride Monohydrate shows that it acts selectively on Bcr- Abl Kinase. To further investigate selectivity of similar compounds a substructure search can be run.

DRUGS & BIOLOGICS KNOWLEDGE AREA: STRUCTURE SEARCH To set up a structure search, select a Knowledge Area Drugs & Biologics in this example and click the Structure Search button to go to the Structure Search Form.

DRUGS & BIOLOGICS KNOWLEDGE AREA: STRUCTURE SEARCH Draw or paste a structure in the structure search window.

DRUGS & BIOLOGICS KNOWLEDGE AREA: STRUCTURE SEARCH Combine a substructure search with a text search by opening the search field menu and selecting a field - in this example, Therapeutic Group. Then open the Then open the corresponding Browse Index to select a term.

DRUGS & BIOLOGICS KNOWLEDGE AREA: STRUCTURE SEARCH Use the Lookup box in the Browse Index to locate terms in the hierarchical Therapeutic Group index. Then click a term -- Oncolytic Drugs in this example -- to copy it to the Search Form.

DRUGS & BIOLOGICS KNOWLEDGE AREA: STRUCTURE SEARCH Click Start or press Return to launch a search for products with this Therapeutic Group classification and that share a similar substructure.

DRUGS & BIOLOGICS KNOWLEDGE AREA: STRUCTURE SEARCH Compounds can be classified quickly and easily by using Filter by Statistics. In this example, select to filter by Molecular Mechanisms.

DRUGS & BIOLOGICS KNOWLEDGE AREA: STRUCTURE SEARCH The chart shows that many of the compounds have more than one mechanism of action. Using the checkbox function, select Bcr-Abl Kinase Inhibitors and click View Subset(s) to view the subset of compounds with this mechanism.

DRUGS & BIOLOGICS KNOWLEDGE AREA: STRUCTURE SEARCH From the original list of product records retrieved that are Oncolytic Drugs and that have a similar structure, these are the compounds that are Bcr-Abl kinase inhibitors. Select the Product List with Structures from the pull-down menu

DRUGS & BIOLOGICS KNOWLEDGE AREA: STRUCTURE SEARCH From this list, structure-activity relationships can be examined. Access to Experimental Pharmacology, Pharmacokinetics/ Metabolism and other data can be obtained through the All Related Information via Quick Search

INFORMATION RETRIEVAL VIA TARGETS & PATHWAYS Select the Targets & Pathways enabled bar

INFORMATION RETRIEVAL VIA TARGETS & PATHWAYS From the Targets & Pathways list obtained, select the Targetscapes option

INFORMATION RETRIEVAL VIA TARGETS & PATHWAYS Click on the Acute Myeloid Leukemia Targescape

INFORMATION RETRIEVAL VIA TARGETS & PATHWAYS to view the molecular landscape for this condition.

SUPPORT/HELP For questions about Integrity s contents or features, send a message via the Help Request / Suggestion Form in Integrity or contact integritysupport @prous.com